President Trump was elected to challenge bureaucratic inertia and ignite American innovation — not to empower the same regulatory philosophy that hampered our national response during the COVID-19 pandemic.

Yet the recent appointment of Dr. Vinay Prasad to lead the FDA’s Center for Biologics Evaluation and Research (CBER) raises serious concerns about the direction of our nation’s health policy.

Dr. Prasad is not new to public discourse.

Read more at Newsmax© 2025 Newsmax. All rights reserved.